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Strategies of management for low-grade squamous intraepithelial lesion (SIL) vary even on a national level. We evaluated the diversity
of management algorithms. This should serve as a source to find a common basis for the management of low-grade SIL. A total of 38
representatives and specialists for colposcopy and cervical pathology were contacted to provide national guidelines,
recommendations or consensus for the management of patients diagnosed with the cytologic diagnosis of low-grade SIL. In all,
23 addressees (60%) responded. The algorithms provided varied considerably. Three variants of algorithms could be defined. Variant
1 was proposed in 14 countries and recommended colposcopy immediately after cytologic diagnosis of low-grade SIL or at the same
time the smear is taken. If available, HPV testing was recommended as a triage option in some countries. Variant 2 is used in three
countries and colposcopy is only performed after a repeated abnormal cytologic result within a 6-month interval or after an optional
test positive for high-risk HPV. Variant 3, as proposed in six countries, takes into account the socio-economic status of the patient: In
patients with poor compliance, ‘see and treat’ management is recommended; in patients where compliance can be assured, follow-up
is carried out by cytology and colposcopy. Global policy of management of patients with low-grade SIL can be summarised in three
algorithms. Quality standards and outcome parameters must be defined in order to improve the management of women with low-
grade SIL.
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Low-grade squamous intraepithelial lesion (SIL) has been defined
as a cytologic diagnosis for patients with smears showing cytologic
criteria of permissive HPV infection or CIN I (Anonymous, 1989).
This classification (Richart, 1990) is also used for histopathologic
diagnosis, and low-grade SIL and low-grade CIN are used
synonymously. The gold standard for the definition of cervical
disease is histopathologic evaluation. However, it has to be kept in
mind that even between expert pathologists inter- and intraobser-
ver variability is high: in a recent study on 194 cervical tissues of
different histologic severity, the agreement rate between five expert
pathologists was 52% for the diagnosis of CIN I (k value 0.6) (Klaes
et al, 2002). Agreement could be improved to 91% (k value 0.9) by
immunohistochemical staining for p16
ink4a a marker associated
with the presence of high-risk HPVs.
In addition to the problem of defining the disease accurately, the
natural course of low-grade SIL is variable: The majority of lesions
(up to 70%) regress and only 10% of low-grade SIL may progress
to high-grade CIN (Nasiell et al, 1986; O ¨stor, 1993; Holowaty et al,
1999). When patients with the cytologic diagnosis of low-grade SIL
are stratified in high-risk HPV negative or high-risk HPV positive
using a GP5þ GP6þ system, all high-risk HPV-negative and 70%
of high-risk HPV-positive smears become normal over a period of
4 years (Nobbenhuis et al, 2001). In this series, 62% of smears were
high-risk HPV positive. Not a single patient out of 64 patients with
the cytologic diagnosis of low-grade SIL progressed to high-grade
CIN (Nobbenhuis et al, 1999). However, using the only commer-
cially available HPV test in clinical practice, Hybrid Capture II
triaging low-grade SIL in regressors and progressors is not
recommended due to the high rate of high-risk HPV positives
with this system (i.e. 83%) (Koutsky et al, 1992; Stoler, 2001).
Since conventional histopathologic evaluation and HPV testing
do not allow to define the biologic potential of low-grade SIL, there
is a wide variety of clinical recommendations for management of
disease. It was the purpose of this study to gain an overview of the
current clinical practice in various countries in order to see if there
is a need for simplification and coordination, for integration of
new markers, and a basis for defining common quality and
outcome parameters for the management of women with low-
grade SIL.
MATERIALS AND METHODS
A letter was sent to 38 different societies and institutions
responsible for the definition and coordination of management
of patients with cervical abnormalities in the various countries. If
published memoranda, recommendations, guidelines or consensus
statements or clinical pathways were available, the authors were
asked to provide the references or to send copies of the published
material. If no such written statements were available, the authors
were asked to give their personal interpretation of the national
strategies. For each country, an algorithm was produced and
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lalgorithms that had only minor discrepancies were combined.
Collection of algorithms was carried out between July and
September 2002 and interpretation of algorithms was presented
at the 20th International Papillomavirus Conference in Paris from
4 to 9 October 2002.
RESULTS
Colposcopy immediately after the cytologic diagnosis of low-grade
SIL is recommended in 11 countries (algorithm 1, Figures 1 and 4).
In three European countries (Hungary, Spain and Yugoslavia) –
where colposcopy is used as part of routine gynaecologic
examination – colposcopy is also considered as an essential tool
for managing low-grade SIL, but the colposcopic examination is
carried out at the time the smear is taken. In Sweden, there are two
different policies for various regions: When a low-grade lesion is
detected in a routine cytologic smear, women in the Stockholm
area are referred for colposcopy within 4 months. In other parts of
Sweden, women with the cytologic diagnosis of low-grade SIL are
followed up according to algorithm 2 (Figures 2 and 4).
Following histologic diagnosis of low-grade SIL after 2–6
months repeat examination by cytology and colposcopy is
performed in all these countries. Persistent low-grade SIL can be
either followed or treated. In health-care systems where HPV
testing is available and recommended, high-risk HPV positive
patients are followed up closely. In the US, HPV-testing is
acceptable not initially, but after 12 months (please see www.ascc-
p.org).
In four countries, cytologic diagnosis of low-grade SIL is
followed up by a repeat smear after 6 months and only, when
repeatedly abnormal on cytology, colposcopy is performed. When
HPV testing is available, high-risk HPV-positive patients undergo
colposcopy and, when abnormal findings are confirmed and
persist for more than 1 year, treatment is performed (algorithm 2,
Figures 2 and 4).
In six countries, management is performed according to the
socio-economic status (algorithm 3, Figures 3 and 4). If
noncompliance can be expected, ‘see and treat’ with different
treatment modalities is recommended. In patients with high
compliance, periodic evaluation by cytology and colposcopy is
recommended and can be augmented by HPV testing. Lesions
persisting for more than 1 year should be treated.
DISCUSSION
Management of women with the cytologic diagnosis of low-grade
SIL varies considerably according to the availability of medical
resources and socio-economic status of women. Since the
histopathologic basis of disease is ill defined and progression
markers are not available, there is a need for standardisation of
treatment in order to guide the patient and clinician to avoid over-
or undertreatment.
Immediate colposcopy after cytologic diagnosis of low-grade SIL
(algorithm 1) is costly and may cause unnecessary stress on
patients and the health system in countries where colposcopy is
not a routine part of the gynaecologic examination. However, delay
of histopathologic confirmation by 6 months or longer (algorithm
2) may lead to underdiagnosis and worsening of prognosis. For
Germany, it has been shown that in patients with the cytologic
diagnosis of low-grade SIL, CIN III is prevalent in 30.2% and
invasive cancer in 1% of patients (Petry et al, 1999). In countries
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Figure 1 Algorithm 1: colposcopy immediately following cytologic
diagnosis of low-grade SIL or in each check-up as a routine examination
described for Austria (Girardi et al, 2001), Germany, Greece, Hong Kong
(Ngam et al, 1999), Hungary, Israel, Italy, Poland, Portugal, Russia, Spain,
Sweden (Stockholm area), USA (Wright et al, 2002), Yugoslavia (Kesic,
2002). This is not the algorithm of the American Society of Colposcopy and
Cervical Pathology (ASCCP), which can be viewed at www.asccp.org.
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Figure 2 Algorithm 2: repeat cytology following cytologic diagnosis of
low-grade SIL described for Croatia (Ljubojeviæ et al, 2002), England
(Duncan, 1997), New Zealand.
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Figure 3 Algorithm 3: management of patients with the cytologic
diagnosis of low-grade SIL according to socio-economic status described
for Argentina, Chile, India, Paraguay, Philippines, Slovakia.
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lwith excellent quality control of cytology, this rate may be lower
and cytologic follow-up may be regarded sufficient.
In health-care systems where high-risk HPV testing is available,
triaging in high-risk HPV-positive and high-risk HPV-negative
lesions is performed (algorithms 1, 2, and 3). However, for clinical
practice, no clear guidelines have been established as to testing of
smears or biopsies and choice of HPV test. Tests that include only
a certain amount of pooled high-risk HPVs and that show
crossreaction between high- and low-risk types are clinically not
useful due to low specificity (Arbyn, 2001). Highly sensitive two-
tier PCR systems including a panel of 50 HPV types applied to
tissue sections and not to smears may be more specific: only 30%
of 453 CIN I contained high-risk HPV types and prevalence and
distribution of HPV types are significantly different from CIN II or
CIN III (Feoli-Fonseca et al, 2001). Thus, HPV systems with
improved sensitivity and specificity may become clinically useful.
Persistent detection of high-risk HPV, integration of high-risk
HPV DNA in the host cell DNA, high viral load, and/or presence of
certain HPV variants may be additional markers for future use.
‘See and treat’ as recommended by various countries (algorithm 3,
Figure 3) on the basis of low-grade SIL by cytology alone, without
biopsy-confirmed CIN I or more severe lesions, is not recom-
mended in the US (please see www.asccp.org) (Figure 4).
There is a need to coordinate the diversing algorithms for the
management of patients with low-grade SIL in order to avoid
overtreatment: The majority of women with diagnosis of low-grade
SIL are young and still desire conception. Standard treatment is
still invasive, either using excisional or ablative procedures, which
are associated with a peri- and postoperative morbidity rate of up
to 10%. The data presented in this enquiry should therefore serve
as a basis to start a discussion of a coordinated effort to improve
the quality and result of the management of this highly prevalent
diagnosis in order to improve women’s health.
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GROUP of SPECIALISTS
Basta, Antoni: Polish Society of Colposcopy and Cervical
Physiopathology, Chair and Department of Gynecology and
Oncology, Jagellonian University, 31-501 Kopernika Street, Kra-
kow 31501, Poland.
Bornstein, Jacob: Israelian Society of Cervical Pathology and
Colposcopy, Department of Obstetrics and Gynecology, Carmel
Medical Center, 7 Michal St, Haifa 34 362, Israel.
Boselli, Fausto: Chief of the Oncologic and Preventive Gynae-
cology Unit, Department of Obstetrics and Gynaecology,
University of Modena and Reggio Emilia, Via Del Pozzo 71, 41
100 Modena, Italy.
Bosze, Peter: Hungarian Society of Cervical Pathology and
Colposcopy, Saint Stephen Hospital, Nagyvarad ter. 1, 1096
Budapest, Hungary.
Chase, Luis Antonio: Paraguay Society of Pathology of the Lower
Genital Tract and Colposcopy, Martin Brizuela 750c/Lillo, Asun-
cio ´n, Paraguay.
Clentworth, Howard: President New Zealand Society of Colpo-
scopy and Cervical Pathology, Women’s Health Service, Capital
Coast Health Bd., Private Bay 7902, Wellington, New Zealand.
Figure 4 World map: Black: countries following algorithm 1; hatched:
Sweden Stockholm area following algorithm 1, other parts following
algorithm 2. Grey: countries following algorithm 2. Chequered: countries
following algorithm 3.
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lCortes-Bordoy, Javier (Montserrat Cararach Tur): Spanish
Society of Cervical Pathology and Colposcopy, Clinica Serosa,
Sor Francinaina Cirer, 1, 07011 Palma, Espan ˜a.
Das, SK: Chief of Gynae Oncology, Rajiv Gandhi Cancer Institute
& Research Centre, Sector-5, Rohini, Delhi 110 085, India.
Diakomanolis, Emmanuel: Hellenic Society of Cervical Pathol-
ogy (Greece), Colposcopy, and Laser, Athens University, 82
Vasilissis Sofias Ave., 11528 Athens, Greece.
Fai, Tam Kar: Secretary General, Hong Kong Society for
Colposcopy and Cervical Pathology, OB/GYN, Queen Mary
Hospital, 102 Pokfulam Rd., Hong Kong.
Girardi, F (Girardi, F, Pickel, H, Joura, EA, Breitenecker, G,
Gitsch, G, Graf, A-H, Neunteufel, W): Abteilung fu ¨r Gyna ¨kologie
und Geburtshilfe, Allgemein-o ¨ffentliches Krankenhaus der Kur-
stadt Baden, Wimmergasse 19, 2500 Baden, O ¨sterreich (Austria).
Grubis ˇiæ, Goran (Ljubojeviæ, N, Babiæ, S, Audy-Jurkoviæ, S,
Ovanin-Rakiæ, A, Grubis ˇiæ, G, and Ljubojeviæ-Grgec, D): Head of
Conservative Gynecology Department at University Hospital
‘Sisters of Mercy’ and President of the Croatian Society for
Colposcopy and Cervical Pathology, 10000 Zagreb, Vinogradska
29, Croatia.
Heinrich, Juergen: German Federation of Cervical Pathology and
Colposcopy, Obstetrics and Gynecology, Klinikum der Hansestadt
Stralsund GmbH, Grosse Parower Street 47-53, 18435 Stralsund,
Germany.
Kesic, Vesna: Yugoslav Society of Cervical Pathology and
Colposcopy, Institute of Obstetrics and Gynecology, University
Clinical Center, 11000 Belgrad, Yugoslavia.
Kitchener, Henry: British Society of Cervical Pathology and
Colposcopy, Department of Obstetrics and Gynecology, St Mary’s
Hospital, Whitworth Park, Manchester, UK.
Limson, Genara A Manuel: Philippines Society of Cervical
Pathology and Colposcopy, Makati Med. Ctr., 2 Amorsolo St.,
Mahati City, Philippines.
Morales, Eduardo: Chilean Society of Cervical Pathology and
Colposcopy (Sociedad Chilena de Colposcopia) Santiago, Chile.
Peluffo, Marcos: Argentinian Society of Cervical Pathology and
Colposcopy, Posadas 1567 PB A (C1112ADA), Buenos Aires,
Argentina.
Pereira da Silva, Daniel: Portugal Society of Colposcopy and
Cervical Pathology, Ty Dr Manuel Bastos Pina 58, 3000 Coimbra,
Portugal.
Rylander, Eva: Karolonska Institutet Danderyds Hospital,
Deputy Head of Department (Division of Obstetrics and Gynae-
cology), SE-18288 Stockholm, Sweden.
Singer, Albert: Whittington Hospital, Department of Women’s &
Children’s Health, Jenner Building, Highgate Hill, London N19
5NF, UK.
S ˇtefanovie `, Julius: Slovak Society of Cervical Pathology and
Colposcopy, National Cancer Institute (Na ´rodny ´y Onkologicky ´
U?stav), Department of Gynecology, Klenova ´ 1, 81310 Bratislava,
Slovak Republic.
Wilkinson, Edward J ( Wright Jr, TC, Cox, JT, Massad, S, Twiggs,
LB, and Wilkinson, EJ): Past President American Society of
Cervical Pathology and Colposcopy, 20 W. Washington St., Suite 1,
Hagerstown, MD 21740, USA.
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